SB400

Summary

A New Hampshire bill concerning the duties and reporting requirements of the therapeutic cannabis medical oversight board reached an impasse after the House refused to accede to a Senate request for a Committee of Conference. A stalled update to the medical oversight board's reporting requirements leaves existing oversight structures unchanged, which affects how medical cannabis programs are monitored and how patients receive program protections.

More New Hampshire Cannabis Bills

• SB624Restricting access to certain hemp-derived products and establishing the offenses of criminal adulteration and distribution of adulterated controlled substances.Passed
• HB1809Establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.In Committee
• SB461Relative to the definition of hemp.In Committee
• HB186Relative to the legalization and regulation of cannabis and making appropriations therefor.In Committee
• SB650Relative to use of cannabis products for therapeutic purposes by alternative treatment centers.Introduced
• SB651Relative to the legalization and regulation of cannabis and making appropriations therefor.Introduced
• HB1796Allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.Introduced
• HB1446Providing that an individual's use of therapeutic cannabis shall not disqualify the individual from the purchase, ownership, or possession of a firearm.Introduced
• CACR19Relative to the personal possession of cannabis. Providing that adults 21 years of age or older shall have the right to possess a modest amount of cannabis intended for their personal consumption.Introduced
• HB1235Legalizing certain quantities of cannabis.Introduced
• SB485Relative to the licensure, regulation and taxation of hemp-based derivative products.Introduced
• SB462Relative to the right of therapeutic cannabis patients to purchase, possess, and transfer firearms in accordance with state law.Introduced